Abstract:Peptides are receiving increasing interest as clinical therapeutics. These highly tunable molecules can be tailored to achieve desirable biocompatibility and biodegradability with simultaneously selective and potent therapeutic effects. Despite challenges regarding up-scaling and licensing of peptide products, their vast clinical potential is reflected in the 60 plus peptide-based therapeutics already on the market, and the further 500 derivatives currently in developmental stages. Peptides are proving effective for a multitude of disease states including: type 2 diabetes (controlled using the licensed glucagon-like peptide-1 receptor liraglutide); irritable bowel syndrome managed with linaclotide (currently at approval stages); acromegaly (treated with octapeptide somatostatin analogues lanreotide and octreotide); selective or broad spectrum microbicidal agents such as the Gram-positive selective PTP-7 and antifungal heliomicin; anticancer agents including goserelin used as either adjuvant or monotherapy for prostate and breast cancer, and the first marketed peptide derived vaccine against prostate cancer, sipuleucel-T. Research is also focusing on improving the biostability of peptides. This is achieved through a number of mechanisms ranging from replacement of naturally occurring L-amino acid enantiomers with D-amino acid forms, lipidation, peptidomimetics, N-methylation, cyclization and exploitation of carrier systems. The development of self-assembling peptides are paving the way for sustained release peptide formulations and already two such licensed examples exist, lanreotide and octreotide. The versatility and tunability of peptide-based products is resulting in increased translation of peptide therapies, however significant challenges remain with regard to their wider implementation. This review highlights some of the notable peptide therapeutics discovered to date and the difficulties encountered by the pharmaceutical industry in translating these molecules to the clinical setting for patient benefit, providing some possible solutions to the most challenging barriers.

The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations

Review on therapeutic potential of peptides: Advancements in synthesis methods, linear and cyclic peptides, and strategies for overcoming challenges

Advancements in peptide-based therapeutics: Design, synthesis and clinical applications

Therapeutic peptides: current applications and future directions

Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems

Transformation of Peptides to Small Molecules in Medicinal Chemistry: Challenges and Opportunities

Peptides for therapeutic applications – challenges and chances

Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases

From Natural Sources to Therapeutics

A Global Review on Short Peptides: Frontiers and Perspectives

Recent Advances and Computational Approaches in Peptide Drug Discovery

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

Overcoming the shortcomings of peptide-based therapeutics

Recent progress in macromolecules: From current therapeutic strategies to theranostic applications

Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients

Novel Peptide Therapeutic Approaches for Cancer Treatment

Biochemistry, Mechanistic Intricacies, and Therapeutic Potential of Antimicrobial Peptides: An Alternative to Traditional Antibiotics

Recent Advances of Nanocarriers for Effective Delivery of Therapeutic Peptides

Therapeutic peptides for coronary artery diseases: in silico methods and current perspectives

Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era

Recent Progress in Solid‐Phase Total Synthesis of Naturally Occurring Small Peptides